relapsing multiple sclerosis
Showing 1 - 25 of 62
Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Not yet recruiting
- Relapsing Multiple Sclerosis
- No intervention
- (no location specified)
Nov 16, 2023
Relapsing Multiple Sclerosis, Multiple Sclerosis Trial (Placebo, Pirtobrutinib)
Not yet recruiting
- Relapsing Multiple Sclerosis
- Multiple Sclerosis
- Placebo
- Pirtobrutinib
- (no location specified)
Oct 24, 2023
Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)
Recruiting
- Relapsing Multiple Sclerosis
- Ublituximab
-
Fort Collins, Colorado
- +1 more
May 26, 2023
Ofatumumab in Portuguese Multiple Sclerosis Patients
Not yet recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- (no location specified)
Mar 30, 2023
Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2
Not yet recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- (no location specified)
Mar 17, 2023
Relapsing Multiple Sclerosis Trial in Worldwide (fenebrutinib, )
Recruiting
- Relapsing Multiple Sclerosis
- Fenebrutinib
- Placebo
-
Fullerton, California
- +16 more
Jan 24, 2023
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United
Recruiting
- Relapsing Multiple Sclerosis
- +2 more
- Autologous Hematopoietic Stem Cell Transplantation
- Best Available Therapy (BAT)
-
Palo Alto, California
- +20 more
Jan 25, 2023
COVID-19 Vaccine in Multiple Sclerosis Participants Treated With
Completed
- Relapsing Multiple Sclerosis
- Ofatumumab
- Covid-19 vaccine
-
Phoenix, Arizona
- +4 more
Jan 23, 2023
Relapsing Multiple Sclerosis Trial in Worldwide (Ofatumumab)
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
-
Cullman, Alabama
- +165 more
Jan 13, 2023
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial in Worldwide (Ocrelizumab IV, Ocrelizumab SC,
Active, not recruiting
- Relapsing Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Ocrelizumab IV
- +5 more
-
Tampa, Florida
- +46 more
Jan 13, 2023
Relapsing Multiple Sclerosis Trial in Worldwide (Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- +5 more
-
Birmingham, Alabama
- +295 more
Jan 13, 2023
Relapsing Multiple Sclerosis Trial in Worldwide (fenebrutinib, teriflunomide, )
Recruiting
- Relapsing Multiple Sclerosis
- fenebrutinib
- +2 more
-
Homewood, Alabama
- +156 more
Jan 5, 2023
Relapsing Multiple Sclerosis Trial in Worldwide (Interferon beta-1a, Ocrelizumab-matching , Ocrelizumab)
Active, not recruiting
- Relapsing Multiple Sclerosis
- Interferon beta-1a
- +3 more
-
Phoenix, Arizona
- +140 more
Jan 2, 2023
Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)
Active, not recruiting
- Relapsing Multiple Sclerosis
- Evobrutinib
- +3 more
-
Cullman, Alabama
- +275 more
Nov 7, 2022
Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)
Active, not recruiting
- Relapsing Multiple Sclerosis
- Evobrutinib
- +3 more
-
Mobile, Alabama
- +278 more
Nov 7, 2022
Relapsing Multiple Sclerosis Trial in Worldwide (Remibrutinib, Teriflunomide)
Recruiting
- Relapsing Multiple Sclerosis
-
Fullerton, California
- +38 more
Aug 12, 2022
s in Patients With Relapsing Multiple Sclerosis
Recruiting
- Relapsing Multiple Sclerosis
- ofatumumab
- +2 more
-
Untermeiting, Bayern, Germany
- +35 more
Aug 12, 2022
Relapsing Multiple Sclerosis Trial in Beijing (Mitoxantrone Hydrochloride Liposome Injection)
Not yet recruiting
- Relapsing Multiple Sclerosis
- Mitoxantrone Hydrochloride Liposome Injection
-
Beijing, Beijing, ChinaXuanwu Hospital Capital Medical University
Aug 9, 2022
RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- Ocrelizumab
-
Dubai, United Arab EmiratesNovartis Investigative Site
Aug 8, 2022
Relapsing Multiple Sclerosis Trial in Worldwide (Remibrutinib, Teriflunomide)
Recruiting
- Relapsing Multiple Sclerosis
-
Hanford, California
- +41 more
Aug 5, 2022
Inflammatory Disease in Multiple Sclerosis
Active, not recruiting
- Relapsing Multiple Sclerosis
- Multiple Sclerosis
- Cerebrospinal and Blood Serum Semaphorin 4A Levels
-
Portland, OregonProvidence St. Vincent Medical Center
May 19, 2022
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome Trial in San Francisco (Ocrelizumab)
Recruiting
- Relapsing Multiple Sclerosis
- Clinically Isolated Syndrome
-
San Francisco, CaliforniaUniversity of California San Francisco
Apr 28, 2022
Relapsing Multiple Sclerosis Trial in Japan, Russian Federation (Ofatumumab, Matching of ofatumumab)
Completed
- Relapsing Multiple Sclerosis
- Ofatumumab
- Matching placebo of ofatumumab
-
Toon-city, Ehime, Japan
- +13 more
Apr 27, 2022